DZP has advised GSK Services sp. z o.o. on its successful bid to submit anti-pneumococcal vaccines to the Polish Ministry of Health, and its successful defense of its selection after a challenge from second place finisher PGF Urtica sp. z o.o.
From January 1 of this year, under Poland's Preventive Vaccination Plan, all new-born babies in the country are to be given the anti-pneumococcal vaccination. Consequently, at the end of October, 2016, the Public Procurement Department at the Ministry of Health announced a tender for the vaccines. According to DZP, "in view of the scope of the supply (all new-born babies), the procedure conducted was the first of its kind in Poland."
After GSK Services's bid was selected by the Public Procurement Departments, second place finisher PGF Urtica appealed the decision to the National Appeal Chamber (NAC).
On December 13, DZP reports, "the NAC dismissed PGF Urtica's appeal against the tender result, thereby confirming that GSK Services' bid had been duly selected, enabling a contract to be signed between the Ministry of Health Public Procurement Department and GSK. The NAC decision was not challenged by way of an appeal to a regional court."
The DZP team consisted of Public Procurement Partner Katarzyna Kuzma and Senior Associate Michal Wojciechowski and Life Sciences Partner Michal Czarnuch and Associate Marcin Pieklak.
